Abstract:
This invention relates to a process for determining the uric acid content of biological material by contacting the biological material with a reagent composition comprised of uricase, catalase, aldehyde dehydrogenase, a lower alkanol, and nicotinamide adenine dinucleotide or nicotinamide adenine dinucleotied phosphate, the improvement which comprises determining the uric acid content in the presence of 2-mercaptosuccinic acid.
Abstract:
A method of and reagent for determining hydrogen peroxide, in which the hydrogen peroxide containing sample is treated with a colouring reagent comprising a peroxidase, a hydrogen donor and an electron or radical acceptor which react stoichiometrically with the hydrogen peroxide to produce a pigment which is then measured colorimetrically. In accordance with the invention the hydrogen donor is specifically a compound of the formula ##STR1## where R.sub.1 is CH.sub.3, C.sub.2 H.sub.5, CH.sub.2 OH, CH.sub.2 CH.sub.2 OH, CH.sub.2 CH.sub.2 NH.sub.2 or COCH.sub.3 ;R.sub.2 is CH.sub.2 OH, CH.sub.2 CH.sub.2 OH, CH.sub.2 CH.sub.2 NH.sub.2, CH.sub.2 NHCOCH.sub.3, CH.sub.2 CH.sub.2 NHCOCH.sub.3 or COCH.sub.3 ;R.sub.3 is H, CH.sub.3, C.sub.2 H.sub.5 or OCH.sub.3 ; andR.sub.4 is H or CH.sub.3.The method and reagent may also be used in the determination of other materials such as cholesterol, phospholipid, glucose and uric acid, by initial treatment with an oxidase thereby quantitatively to produce hydrogen peroxide which is then determined colorimetrically by the method of the invention.
Abstract:
An aqueous solution useful in connection with a redox type spectrophotometric or colorimetric determination of uric acid in a biologic fluid is disclosed. The solution contains either a multivalent metallic ion reducible to a lower valence state by uric acid, a water soluble chelating compound capable of complexing with a metallic ion after reduction by uric acid to yield, in complexed form, a colored complex, or a combination of said ion and said chelating compound. The solution also contains, as an added constituent, imidazole, an alpha-amino acid, or a combination thereof. This constituent is present in an amount such that, when said solution contains a biologic fluid containing protein and uric acid, a buffer system such that the pH of the solution is 6 to 12, and a multivalent metal ion, the protein in the fluid does not significantly reduce said multivalent ions present in the solution.
Abstract:
Compositions and methods are described for the determination of specific components in a biological fluid by a quantitative colorimetric determination of an oxidizing agent, e.g., hydrogen peroxide, produced in the biological fluid by an appropriate enzyme, said compositions comprising an aromatic amine component, a hydrazone component and a citric and/or maleic acid component.
Abstract:
A solid, water-soluble substantially anhydrous, storage-stable reagent formulation for use in conducting a clinical diagnostic test on a biological specimen is provided. The reagent formulation comprises a mixture containing a reagent capable of participating in a test reaction to effect a measurable change in a test system; and a nitrogen bearing polyoxyalkylene nonionic surfactant. The surfactant has a structure corresponding to that obtained when ethylene diamine is reacted sequentially with propylene oxide and ethylene oxide in the presence of a catalyst. The polyoxypropylene chains of said surfactant have an average molecular weight of between about 750 and about 6750. Methods of preparing the reagent formulations and methods of using them to conduct clinical diagnostic tests are also provided.
Abstract:
An enzyme reagent formulation for use in assaying a biological specimen for uric acid is prepared as a granular, water-soluble, anhydrous, storage-stable mixture containing uricase, potassium chloride, mannitol, gum acacia, bovine serum albumin, glycine, sodium carbonate and a nitrogen containing polyoxyalkylene nonionic surfactant obtained by the sequential reaction of ethylenediamine with propylene oxide and ethylene oxide in the presence of a catalyst. The surfactant contains polyoxypropylene chains having an average molecular weight of between about 750 and about 6750, and polyoxyethylene chains constituting between about 10 and about 80 weight percent of the surfactant. The surfactant has an advantageous effect upon granulation, dissolution and storage stability of the reagent formulation.
Abstract:
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.